Guardant Health (NASDAQ:GH – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Stephens in a report released on Friday, Benzinga reports. They presently have a $210.00 target price on the stock. Stephens‘s price objective would indicate a potential upside of 48.06% from the company’s previous close.
Other research analysts have also recently issued reports about the stock. Guggenheim boosted their target price on shares of Guardant Health from $190.00 to $200.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Royal Bank Of Canada lifted their price target on shares of Guardant Health from $185.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Stifel Nicolaus upped their price objective on shares of Guardant Health from $130.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Mizuho raised their target price on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Finally, Morgan Stanley lifted their target price on Guardant Health from $185.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Guardant Health presently has an average rating of “Moderate Buy” and a consensus price target of $191.48.
Get Our Latest Analysis on Guardant Health
Guardant Health Trading Down 2.6%
Shares of GH stock opened at $141.84 on Friday. The company’s fifty day simple moving average is $167.32 and its 200-day simple moving average is $133.64. Guardant Health has a 52 week low of $74.55 and a 52 week high of $191.05. The company has a market cap of $19.19 billion, a PE ratio of -38.30 and a beta of 1.67.
Guardant Health (NASDAQ:GH – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.46. The business had revenue of $360.98 million for the quarter, compared to analysts’ expectations of $350.72 million. During the same period last year, the company posted ($0.74) earnings per share. The firm’s revenue for the quarter was up 36.1% on a year-over-year basis. Equities research analysts expect that Guardant Health will post -3.28 EPS for the current fiscal year.
Insider Transactions at Guardant Health
In related news, insider Terilyn J. Monroe sold 3,842 shares of the firm’s stock in a transaction on Wednesday, November 18th. The stock was sold at an average price of $142.41, for a total transaction of $547,139.22. Following the transaction, the insider directly owned 21,058 shares in the company, valued at $2,998,869.78. This trade represents a 15.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alex M. Azar II sold 826 shares of Guardant Health stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $175.00, for a total transaction of $144,550.00. Following the completion of the transaction, the director directly owned 825 shares of the company’s stock, valued at approximately $144,375. This represents a 50.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 19,566 shares of company stock worth $3,320,185 in the last quarter. Insiders own 5.60% of the company’s stock.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Financial Network Wealth Advisors LLC raised its stake in Guardant Health by 17.2% during the third quarter. Financial Network Wealth Advisors LLC now owns 423 shares of the company’s stock worth $75,000 after acquiring an additional 62 shares during the period. Yousif Capital Management LLC grew its holdings in shares of Guardant Health by 6.2% during the third quarter. Yousif Capital Management LLC now owns 1,587 shares of the company’s stock valued at $283,000 after purchasing an additional 93 shares during the last quarter. Allworth Financial LP grew its holdings in shares of Guardant Health by 12.4% during the second quarter. Allworth Financial LP now owns 1,072 shares of the company’s stock valued at $161,000 after purchasing an additional 118 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Guardant Health by 14.5% during the 2nd quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock worth $145,000 after purchasing an additional 122 shares during the period. Finally, Slow Capital Inc. raised its position in shares of Guardant Health by 0.3% during the 3rd quarter. Slow Capital Inc. now owns 52,683 shares of the company’s stock worth $9,397,000 after purchasing an additional 136 shares during the period. 92.60% of the stock is currently owned by institutional investors.
Guardant Health Company Profile
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
Further Reading
- Five stocks we like better than Guardant Health
- Airfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter Test
- Hard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
- 2 Utility Stocks May Offer Relief From AI Volatility, But Rates Are the Real Story
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
